

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of the claims in this application.

1                   1.     **(Original)**     A method for eliciting an immune response in a subject  
2 comprising administering an immunogenically effective amount of a peptide or protein  
3 antigen comprising one or more T cell epitope(s) coordinately with a non-viral vector  
4 comprising a polynucleotide encoding a T cell co-stimulatory molecule.

1                   2.     **(Original)**     The method of claim 1, wherein the peptide or protein  
2 antigen comprises a T cell epitope of a tumor antigen or viral antigen.

Claims 3 - 5. **(Cancelled)**

1                   6.     **(Original)**     A method for eliciting an immune response in a subject  
2 comprising administering an immunogenically effective amount of a protein antigen  
3 comprising at least one T cell epitope coordinately with a non-viral vector comprising a  
4 polynucleotide encoding a T cell co-stimulatory molecule.

1                   7.     **(Original)**     The method of claim 2, wherein the viral antigen is  
2 selected from a human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C  
3 virus (HCV), herpes simplex virus (HSV) or human papilloma virus (HPV) antigen.

1                   8.     **(Original)**     The method of claim 7, wherein the peptide antigen  
2 comprises at least nine contiguous amino acids of a HPV antigenic protein.

Claims 9 through 10. **(Cancelled)**

1                   11.    **(Original)**     The method of claim 1, wherein the co-stimulatory  
2 molecule is selected from B7-1, B7-2, B7-3, B7-H, ICAM1, ICAM2, ICAM3, LFA1, LFA2  
3 or LFA3.

1                   12.    **(Original)**     The method of claim 11, wherein the co-stimulatory  
2 molecule is B7-1.

1                   13.    **(Original)**    The method of claim 1, wherein the peptide antigen and  
2 non-viral vector encoding one or more T cell co-stimulatory molecules are administered to  
3 the subject simultaneously as a mixture in a pharmaceutically acceptable carrier or diluent.

1                   14.    **(Original)**    The method of claim 1, wherein the peptide antigen and  
2 non-viral vector encoding the T cell co-stimulatory molecule are administered separately to  
3 the subject in a sequential vaccination protocol.

1                   15.    **(Original)**    The method of claim 1, wherein the peptide antigen and  
2 non-viral vector encoding the T cell co-stimulatory molecule are administered to proximal  
3 target sites selected from the same, or closely-adjacent, intradermal, subcutaneous, mucosal  
4 or intratumoral sites.

1                   16.    **(Original)**    The method of claim 1, wherein the non-viral vector is  
2 selected from a RNA or DNA vector.

1                   17.    **(Original)**    The method of claim 1, wherein the non-viral vector  
2 comprises a naked DNA vector having the polynucleotide encoding the co-stimulatory  
3 molecule operably linked to regulatory elements necessary for expression of the co-  
4 stimulatory molecule in eukaryotic cells.

Claims 18 - 31.       **(Cancelled)**